丁志英 - 吉林大学

个人简介

丁志英（1964.08—），女，博士学位，研究生学历，主要从事过医院药学工作（10年）和药学教学及科研（2001年—现在），担任《中国生化药物杂志》编委，吉林省药学会药剂分会委员。

研究领域

合理用药、给药方案设计、纳米化妆品及纳米饮料的研究。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[1] Zhiying Ding , Min Wu, Qiushi Guo, Xiaohong Yang, Bingren Zhang﹡. Encapsulation of a Flavonoid-rich Allium cepa L. var. agrogatum Don Extract in beta-Cyclodextrin for Transdermal Drug Delivery. Journal Of Agricultural And Food Chemistry [J], 2013,61(20):4914--4920. DOI: 10.1021/jf302325d. SCI: 2.906. [2] Zhiying Ding , Min Wu, Yue Zhang, Yufang He, Jing Wang, Qiushi Guo, Bingren Zhang﹡. Systemic Delivery of Allium cepa L.var agrogatum Don Flavonoid-Rich Extract via the Percutaneous Route Using a Microemulsion System. Asian Journal of Chemistry[J], 2013,25(15):. SCI: 0.253. [3] Zhiying Ding, Min Wu, Qiushi Guo, Bingren Zhang﹡. Lipid rafts inducing percutaneous transport of ginsenoside nanoemulsion across stratum corneum cells. Journal controlled release. 2013，November，172,1(11)：e67.SCI: 7.633. [4] Qiushi Guo, Yanqing Song, Min Wu, Qiuye Guo,Zhiying Ding*. Evaluation of liposomes with entrapped supramolecular complexes of Andro with hydroxypropyl-β-cyclodextrin for targeted drug delivery, Journal of Controlled Release,2013,172,1(11):e61-2. [5] Min Wu, Jing Wang, Qian Chen, Zhiying Ding﹡. Crossing the SC : targeting and mechanism of Andro via nanoemulsion system, Journal of Controlled Release,2013,172,1（11）:e56. [6] Bingren Zhang, Min Wu, Yu Dong, Jing Wang, Zhiying Ding﹡.Low-voltage electroporation mediated transcutaneous targeting Delivery of Andro inclusion liposome, Journal of Controlled Release,2013,172，1：e16. [7] Zhiying Ding,Qingbo Li,Xiaohong Yang.Biopharmaceutic Evaluation of Andrographolide, Drug Metabolism Reviews,2008，40 ，Supplement 2. [8] Tingting Lin,Zhiying Ding, Junqiu Liu.Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression, European Journal of Cancer,Volume 47, 2011（8）, 1890-1907 [9] Tingting Lin,Zhiying Ding, Junqiu Liu.2-Tellurium-bridged ß-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-kB suppression, Carcinogenesis,vol.32 no.2 pp.154–167, 2010.